China Resources Pharma's recombinant coagulation factor IX has received the clinical trial approval notice for drugs in mainland China

China Resources Pharmaceutical (03320.HK) announced that its subsidiary China Resources BOYA Biotechnology Group received the Clinical Trial Approval Notice for Human Coagulation Factor IX issued by the National Medical Products Administration. This product is used for bleeding treatment in patients with Coagulation Factor IX deficiency (Hemophilia B)